top of page
  • Patient Education

Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy

Updated: Jan 27

  • Patient Education: Idecabtagene Vicleucel


  • ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

IDE-CEL (Abecma) CART Cell Therapy for Multiple Myeloma

Idecabtagene Vicleucel ( Abecma)

NIH National cancer institute - cancer.gov site info

This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s): Abecma

FDA Approved: Yes

 

MedlinePlus Information

A lay language summary of important information about this drug that may include the following:

warnings about this drug,

what this drug is used for and how it is used,

what you should tell your doctor before using this drug,

what you should know about this drug before using it,

other drugs that may interact with this drug, and

possible side effects.

 

Information on Abecma website

 

INTERNATIONAL MYELOMA FOUNDATION:


Understanding ABECMA® (idecabtagene vicleucel)


IMF Understanding Series


IMF Resource Library


Current FDA-Approved Medications for Multiple Myeloma Treatment

 

HEALTH TREE UNIVERSITY MYELOMA:

All about Abecma (Idecabtagene Vicleucel)


HealthTree University for Multiple Myeloma Lectures


Health Tree University Myeloma Videos

 

MULTIPLE MYELOMA RESERACH FOUNDATION:


Standard Treatments - (BCMA)-directed personalized immunotherapy Abecma


MMRF Education Programs


MMRF Videos

 

References ABECMA- idecabtagene vicleucel:


FDA Label Prescribing Information (Revised 03/2021)



Drug Label Information at DAILYMED - NIH-National Library of Medicine


Other Resources

 

- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -

* Belantamab mafodotin (Withdrawn from United States market)



Comments


Commenting has been turned off.
Posts Archive
bottom of page